Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection

Journal of Clinical Pharmacology

Volumn 54, Issue 4, 2014, Pages 378-385

  Custodio, Joseph M ^a   Yin, Xiang ^a   Hepner, Mischa ^a   Ling, Kah Hiing J ^a   Cheng, Andrew ^a   Kearney, Brian P ^a   Ramanathan, Srinivasan ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

emtricitabine; food; pharmacokinetics; rilpivirine; tenofovir

Indexed keywords

EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; RILPIVIRINE; TENOFOVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EMTRICITABINE; FOOD; PHARMACOKINETICS; RILPIVIRINE; TENOFOVIR;

ADENINE; ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DEOXYCYTIDINE; DRUG COMBINATIONS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NITRILES; ORGANOPHOSPHONATES; PYRIMIDINES; TABLETS; YOUNG ADULT;

EID: 84898609122     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.210     Document Type: Article

References (11)

1. Edurant™ US Prescribing Information.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL.pdf
3. Cohen C, Wohl D, Arribas J, et al., STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/ Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection Journal of the International AIDS Society. 2012, 15 (Suppl 4): 18221.
4. Fisher M, Palella F, Tebas P, et al. SPIRIT: switching to emtricitabine/rilpivirine/tenofovir DF single-tablet regimen from boosted protease inhibitor maintains HIV suppression at week 48. Abstracts of the Eleventh International Congress on Drug Therapy in HIV Infection. Journal of the International AIDS Society. 2012, 15 (Suppl 4): 18275.
5. Hoetelmans R, Van Heeswijk R, Kestens D, et al. Effect of food and multiple-dose pharmacokinetics of TMC278 as an oral tablet formulation: Healthy volunteers. International AIDS Society Conference, Rio De Janerio, July 24-27. 2005, Poster No. TuPe3. 1 B10.
6. Crauwels HM, van Heeswijk RPG, Bollen A, et al. Impact of food and different meal types on the pharmacokinetics of rilpivirine. J Clin Pharmacol 2013; 53 (8): 834-8840.
7. Mathias A, Menning M, Wei L, et al. Bioequivalence of the coformulation of emtricitabine/rilpivirine/tenofovir DF. 18th International AIDS Conference, Vienna, Austria. 2010, Poster LB PE-17.
8. Complera® US Prescribing Information, 2013.
9. Emtriva® US Prescribing Information, 2013.
10. Truvada® US Prescribing Information, 2013.
11. German P, Warren, D, Wei L, et al. Effect of food on the pharmacokinetics of elvitegravir, emtricitabine, tenofovir DF, and the pharmacoenhancer GS-9350 as a fixed-dose combination tablet. 49th Interscience conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA 2009. Poster A1-1300.